Killed but metabolically active mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin

Journal of Urology

Volumn 191, Issue 5, 2014, Pages 1422-1428

  Secanella Fandos, Silvia ^a   Noguera Ortega, Estela ^a   Olivares, Francesc ^a   Luquin, Marina ^a   Julián, Esther ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

BCG vaccine; immunotherapy; inactivated; metabolic phenomena; urinary bladder neoplasms; vaccines

Indexed keywords

BCG VACCINE; INTERLEUKIN 6; INTERLEUKIN 8; GAMMA INTERFERON; INACTIVATED VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; KILLED BUT METABOLICALLY ACTIVE BACILLUS CALMETTE GUERIN VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLADDER CARCINOMA; BLADDER TUMOR; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CYTOKINE PRODUCTION; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MYCOBACTERIUM BOVIS BCG; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER IMMUNIZATION; CANCER INHIBITION; CELL CONTACT; CELL CULTURE; CELL PROLIFERATION; ELECTRON MICROSCOPY; GROWTH INHIBITION; HEAT TREATMENT; IMMUNE RESPONSE; NORMAL HUMAN; SUPERNATANT; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET IRRADIATION;

BCG VACCINE; IMMUNOTHERAPY; INACTIVATED; METABOLIC PHENOMENA; URINARY BLADDER NEOPLASMS; VACCINES;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; HUMANS; MYCOBACTERIUM BOVIS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; VACCINES, INACTIVATED;

EID: 84899045833     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.12.002     Document Type: Article

References (30)

1. A.B. Alexandroff, S. Nicholson, and P.M. Patel et al. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer Immunotherapy 2 2010 551
2. P. Whelan The treatment of non-muscle-invasive bladder cancer with intravesical chemotherapy and immunotherapy Eur Urol 6 suppl. 2007 568
3. O.Y. Gonzalez, D.M. Musher, and I. Brar et al. Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy Clin Infect Dis 36 2003 140
4. Y. Zhang, H.E. Khoo, and K. Esuvarananthan Effects of bacillus Calmette-Guerin and Interferon-a2b on cytokine production in human bladder cancer cell lines J Urol 161 1999 977
5. A. Thanhäuser, A. Böhle, and H.D. Flad et al. Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro Cancer Immunol Immunother 37 1993 105
6. B. Zbar, E. Ribi, and T. Meyer et al. Immunotherapy of cancer: regression of established intradermal tumors after intralesional injection of mycobacterial cell walls attached to oil droplets J Natl Cancer Inst 52 1974 1571
7. C. Sanger, A. Busche, and G. Bentien et al. Immunodominant Pst1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer BMC Cancer 4 2004 86
8. A.R. Zlotta, J.P. Van Vooren, and O. Denis et al. What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer? Int J Cancer 87 2000 844
9. D.R. Kelley, T.L. Ratliff, and W.J. Catalona et al. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results J Urol 134 1985 48
10. N. Ikeda, I. Toida, and A. Iwasaki et al. Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): a role of BCG internalization into tumor cells Int J Urol 9 2002 29
11. T.W. Dubensky Jr., J. Skoble, and P. Lauer et al. Killed but metabolically active vaccines Curr Opin Biotechnol 23 2012 917
12. D.M. Magnani, J.S. Harms, and M.A. Durward et al. Nondividing but metabolically active gamma-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice Infect Immun 77 2009 5181
13. D. Hayashi, T. Takii, and N. Fujiwara et al. Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guérin (BCG) substrains FEMS Immunol Med Microbiol 56 2009 116
14. M. Murata Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors Cancer Sci 99 2008 1435
15. G.A. Shin, J.K. Lee, and R. Freeman et al. Inactivation of Mycobacterium avium complex by UV irradiation Appl Environ Microbiol 74 2008 7067
16. M.M. Garcia, B.W. Brooks, and R.B. Stewart et al. Evaluation of gamma radiation levels for reducing pathogenic bacteria and fungi in animal sewage and laboratory effluents Can J Vat Res 51 1987 285
17. T.P. Primm, and S.G. Franzblau Recent advances in methodologies for the discovery of antimycobacterial drugs Curr Bioact Compd 3 2007 201
18. Y. Uenishi, K. Kawabe, and T. Nomura et al. Morphological study on Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105) J Microbiol Methods 77 2009 139
19. S. Secanella-Fandos, M. Luquin, and E. Julián Connaught and Russian strains showed the highest direct antitumor effects of different bacillus Calmette-Guérin substrains J Urol 189 2013 711
20. W. Liu, M.A. O'Donnell, and X. Chen et al. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro Cancer Immunol Immunother 58 2009 1647
21. T. Kato, V. Bilim, and K. Yuuki et al. Bacillus Calmette-Guerin and BCG cell wall skeleton suppressed viability of bladder cancer cells in vitro Anticancer Res 30 2010 4089
22. G.N. Thalmann, A. Sermier, and C. Rentsch et al. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin J Urol 164 2000 2129
23. S. Brandau, A. Böhle, and A. Thanhäuser et al. In vitro generation of bacillus Calmette-Guérin-activated killer cells Clin Infect Dis 31 suppl. 2000 S94
24. Y. Luo, H. Yamada, and D.P. Evanoff et al. Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells Clin Exp Immunol 146 2006 181
25. A. Böhle, A. Thanhäuser, and A.J. Ulmer et al. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon J Urol 150 1993 1932
26. R.W. Baldwin, A.J. Cook, and D.G. Hopper et al. Radiation-killed BCG in the treatment of transplanted rat tumors Intern J Cancer 13 1974 743
27. N. Willmott, M.V. Pimm, and R.W. Baldwin Quantitative comparison of BCG strains and preparations in immunotherapy of a rat sarcoma J Natl Cancer Inst 63 1979 787
28. J.W. Kreider, G.L. Bartlett, and D.M. Purnell Immunotherapeutic effectiveness of BCG inactivated by various modalities Cancer 46 1980 480
29. J.H. Günther, M. Frambach, and I. Deinert et al. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49) J Urol 161 1999 1702
30. E.C. De Boer, S.J. Rooijakkers, and D.H. Schamhart et al. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guérin determine the succeeding Th1 response J Urol 170 2003 200